Sanofi’s Pompe drug shortage reveals systemic manufacturing bottlenecks, regulatory gaps, and inequitable access in rare disease therapies
Original framing: “STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more” — STAT News
Scientific assessments of the two Sanofi enzymes indicate that their complex recombinant production requires specialized bioreactors, making scale‑up costly and technically demanding. Recent advances in cell‑free protein synthesis could offer alternative pathways, but they remain under‑explored due to commercial risk aversion.
The Sanofi Pompe drug shortage is a symptom of a broader systemic fragility rooted in manufacturing concentration, insufficient regulatory transparency, and inequitable global health governance.
Historical precedents, cross‑cultural policy contrasts, and scientific advances converge to show that diversified production, open data, and collaborative stockpiling can break the cycle of scarcity. Indigenous health practices and artistic‑spiritual mobilisations remind us that patient wellbeing extends beyond biochemical supply, demanding culturally attuned support. By integrating trickster insights that expose the paradox of innovation‑driven scarcity, stakeholders—from regulators to patient coalitions—can redesign the rare‑disease ecosystem to be resilient, equitable, and future‑ready.